Industry Educational Session - Quality of Life in Myeloma: Evolving Patient Needs, Innovations in Assessment and the Future of Myeloma Clinics - Sponsored by Pfizer
Tracks
-
| Tuesday, April 21, 2026 |
| 12:30 PM - 1:15 PM |
| Room 12, Upper Level |
Details
PP-UNP-GBR-14445/March 2026
This non-promotional symposium is organised and funded by Pfizer Ltd and is intended for UK healthcare professionals only.
Join Dr Jaimal Korthari and Dr Sally Moore for a forward-looking discussion exploring the impact of multiple myeloma on patients’ quality of life (QoL). The session will explore how patient reported outcomes (PROMs) and emerging technologies, including AI enabled assessment tools, can support QoL measurements, alongside providing insights into the future direction of myeloma clinics.
Speaker
Dr. Jaimal Kothari
Consultant Haematologist
Oxford University
Speaker One
Dr Jaimal Kothari is a Consultant Haematologist at Oxford University Hospitals and Clinical Lead for Myeloma for Oxford and Thames Valley. He completed his haematology training at University College London Hospitals with his clinical and research interests focusing on multiple myeloma and Waldenström macroglobulinaemia. He is an active trialist and has acted as principle investigator on a number of myeloma studies.
Dr. Sally Moore
Consultant Haematologist
University Hospitals Bristol & Weston NHS Foundation Trust
Speaker Two
Dr Sally Moore is a haematology consultant at University Hospitals Bristol and Weston specialising in plasma cell dyscrasias, for which she is the local and regional lead. Sally is a member of the UK Myeloma Society Executive committee and UK Myeloma Research Alliance. With interests in frailty and infection in myeloma, she is a co-investigator for the CRUK funded UKMRA frailty trial, iFIT. She is a co-lead of the NIHR National Myeloma Registry and is a co-founder of the Southwest Myeloma Group.
